TC
KYMR icon

TwinBeech Capital’s Kymera Therapeutics KYMR Stock Holding History

TwinBeech Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-39,133
Closed -$900K – 780
2023
Q2 		$900K Buy
+39,133
New +$1.12M 0.02% 467
2022
Q4 		– Sell
-47,468
Closed -$1.03M – 823
2022
Q3 		$1.03M Buy
+47,468
New +$1.25M 0.03% 444

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TwinBeech Capital's KYMR Position: Q3 2023 in Review

TwinBeech Capital sold out of Kymera Therapeutics (KYMR) in Q3 2023, closing a stake of 39,133 shares — an estimated $900K sold.

TwinBeech Capital first reported a position in KYMR in Q3 2022 and held it in 2 quarters. The position peaked at $1.03M in Q3 2022. 121 funds tracked by Wall St. Rank hold KYMR as of Q3 2023.

  • TwinBeech Capital reported no remaining Kymera Therapeutics position as of Q3 2023 after selling out during the quarter.
  • TwinBeech Capital sold 39,133 Kymera Therapeutics shares in Q3 2023, an estimated $900K.
  • TwinBeech Capital first reported a position in Kymera Therapeutics in Q3 2022 and held it in 2 quarters.
  • TwinBeech Capital's Kymera Therapeutics position peaked at $1.03M in Q3 2022.
  • 121 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2023.

Based on TwinBeech Capital's 13F filing for Q3 2023, filed 14 Nov 2023.